In 2016 The GBS|CIDP Foundation awarded a research grant to Eduardo Nobile-Orazio, MD, PhD, FAAN, Professor of Neurology Neuromuscular and Neuroimmunology Service at Milan University. Dr. Nobile-Orazio’s 2016 study titled: An Italian Multicenter Network for the diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and of its variants, contributed to the 2019 article: Risk factors for chronic inﬂammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database., published by the EAN (European Academy of Neurology). Update: GBS|CIDP Foundation Research 2016 Grant Recipient, Dr. Eduardo Nobil-Orazio, published in Journal of Neurology, Journal of Neuroimmunology, and Wiley Online Library, and EAN.Read More about Your Donations in Action
INCbase Update Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder that affects different people in different ways. The symptoms, treatment response, and disease course may vary from person to person, or even in the same person at different stages of the disease. As previously reported in 2017, INCbase is a study that intends to…Read More about INCbase
Research grants are made possible through the benevolence of many sources, including the Helen S. Manheimer Research Fund, contributions from individuals who have been personally touched by GBS, CIDP, or variants, and by several commercial sources. Through the generosity of these contributors, to whom the Foundation is most grateful, we are able continue our Research…Read More about 2020 GBS|CIDP Foundation International Research Grants Announced!
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19Read More about Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.Read More about Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy